Has Matthew Smith, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,860,042 in general payments to Matthew Smith, MD across 210 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matthew Smith, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matthew Smith, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matthew Smith, MD

Orthopaedic Surgery · Columbia, MONPI 1518034404

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $2,292,052 of the $2,860,042 with a category attached, or 80.1%. 10 manufacturers reported payments, led by Ignite Orthopedics, LLC at 53.4% of the total. 2025 is the largest year on record at $872,381, more than ten times the $30,870 reported in 2019. Among orthopaedic surgery clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,860,042in general payments, 2019–2025

Across 210 payments — averaging $13,619 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Ignite Orthopedics, LLC$1.5M
Depuy Synthes Products, Inc.$1.2M
Medical Device Business Services, Inc.$130K
Elite Orthopedics, LLC$5K
Arthrex$2K
Zimmer Biomet$2K
plus $557 from 4 others

$169,375in research payments, 2019–2025

Across 40 payments — averaging $4234.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Arthrex$122K
Stryker$48K

$977,487in ownership & investment interests, 2019–2025

Across 6 payments — averaging $162,915 each. An ownership or investment interest held by the physician or an immediate family member.

Ignite Orthopedics, LLC$977K

What the payments were for

Royalty or licence$2,292,05280%
Consulting fees$175,5256%
Speaking & faculty fees$2,0000%
Travel & lodging$13,7010%
Food & beverage$4,2280%
Education$2,9100%
Ownership interest$369,62713%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Ignite Orthopedics, LLC	35	$1,526,054
Depuy Synthes Products, Inc.	51	$1,194,976
Medical Device Business Services, Inc.	87	$129,819
Elite Orthopedics, LLC	14	$4,654
Arthrex	5	$2,061
Zimmer Biomet	6	$1,921
Johnson & Johnson	7	$374
Stryker	1	$88
Sanofi Pasteur Inc.	3	$56
Catalyst Orthoscience	1	$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,860,042 in reported general payments places this provider in the 95th percentile of 455 orthopaedic surgery providers in Missouri.

See all orthopaedic surgery providers in Missouri →

Medicare billing

Part B allowed, 2024

$142,688

Medicare patients

315

Services billed

565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Oxycodone Hcl	28	$89
Cephalexin	12	$22

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Columbia

Kurt BormannColumbia$203K
Bhajanjit BalColumbia$171K
Mauricio KfuriColumbia$65K
Michael GhassibiColumbia$37K
Patrick RowanColumbia$36K
Jay KeenerSaint Louis$2.2M
John WatsonSaint Louis$1.7M
Peter ChalmersSaint Louis$603K
Katherine BurnsBridgeton$491K
Jeremy StattonLees Summit$457K

See the full list for Missouri →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →